Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines funds procurers’ innovations for better cancer care.
Phase 1 including first-in-human clinical trials supports research teams testing biomarker-guided medicines or multi-modal treatments to establish early safety and efficacy for rare cancers.
Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research funds teams studying cancer care to improve equity.
Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers supports cancer infrastructures to study diagnosis and treatment and improve access to care.
Reinforcing synergies between experimentation spaces and innovation procurement supports public buyers' joint procurement to develop and test innovative solutions that modernise public services.
Open grounds for future pre-commercial procurement of innovative security technologies supports end-user and public-procurer consortia preparing joint procurement to mature and compare security technologies.